| Bioactivity | SARS-CoV-2 Mpro-IN-6 is a covalent, irreversible and selective SARS-CoV-2 Mpro inhibitor with an IC50 of 0.18 μM. SARS-CoV-2 Mpro-IN-6 does not inhibit human cathepsins B, F, K, and L, and caspase 3[1]. |
| Target | IC50: 0.18 μM (SARS-CoV-2 Mpro) |
| Invitro | SARS-CoV-2 Mpro-IN-6 (GD-9) 对 SARS-CoV-2 显示出良好的抗病毒效力 (ECsub>50 = 2.64 μM)。SARS-CoV-2 Mpro-IN-6 在 Vero E6 细胞 中表现出一定的细胞毒性（CCsub>50 为 12.51 μM）[1]。 |
| Name | SARS-CoV-2 Mpro-IN-6 |
| CAS | 2768834-48-4 |
| Formula | C18H18Cl3N3O2S |
| Molar Mass | 446.78 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Shenghua Gao, et al. Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors. J Med Chem. 2022 Dec 22;65(24):16902-16917. |
SARS-CoV-2 Mpro-IN-6
CAS: 2768834-48-4 F: C18H18Cl3N3O2S W: 446.78
SARS-CoV-2 Mpro-IN-6 is a covalent, irreversible and selective SARS-CoV-2 Mpro inhibitor with an IC50 of 0.18 μM. SARS
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.